These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 30518630)

  • 1. Assessment of in vitro effects of direct thrombin inhibitors and activated factor X inhibitors through clot waveform analysis.
    Wakui M; Fujimori Y; Katagiri H; Nakamura S; Kondo Y; Kuroda Y; Nakagawa T; Shimizu N; Murata M
    J Clin Pathol; 2019 Mar; 72(3):244-250. PubMed ID: 30518630
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Distinct features of bivalent direct thrombin inhibitors, hirudin and bivalirudin, revealed by clot waveform analysis and enzyme kinetics in coagulation assays.
    Wakui M; Fujimori Y; Nakamura S; Kondo Y; Kuroda Y; Oka S; Nakagawa T; Katagiri H; Murata M
    J Clin Pathol; 2019 Dec; 72(12):817-824. PubMed ID: 31366633
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterisation of antithrombin-dependent anticoagulants through clot waveform analysis to potentially distinguish them from antithrombin-independent inhibitors targeting activated coagulation factors.
    Wakui M; Fujimori Y; Nakamura S; Oka S; Ozaki Y; Kondo Y; Nakagawa T; Katagiri H; Murata M
    J Clin Pathol; 2021 Apr; 74(4):251-256. PubMed ID: 32796051
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro study of the anticoagulant effects of edoxaban and its effect on thrombin generation in comparison to fondaparinux.
    Samama MM; Mendell J; Guinet C; Le Flem L; Kunitada S
    Thromb Res; 2012 Apr; 129(4):e77-82. PubMed ID: 21851967
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A correlation of thrombin generation assay and clot waveform analysis in patients on warfarin.
    Cheong MA; Tan CW; Wong WH; Kong MC; See E; Yeang SH; Koh SK; Shim YT; Lee LH; Ng HJ
    Hematology; 2022 Dec; 27(1):337-342. PubMed ID: 35255239
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis and Thrombin, Factor Xa and U46619 Inhibitory Effects of Non-Amidino and Amidino N²-Thiophenecarbonyl- and N²-Tosylanthranilamides.
    Lee SH; Lee W; Nguyen T; Um IS; Bae JS; Ma E
    Int J Mol Sci; 2017 May; 18(6):. PubMed ID: 28561744
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Edoxaban: Impact on routine and specific coagulation assays. A practical laboratory guide.
    Douxfils J; Chatelain B; Chatelain C; Dogné JM; Mullier F
    Thromb Haemost; 2016 Jan; 115(2):368-81. PubMed ID: 26510969
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Innovative Three-Step Microwave-Promoted Synthesis of
    Santana-Romo F; Lagos CF; Duarte Y; Castillo F; Moglie Y; Maestro MA; Charbe N; Zacconi FC
    Molecules; 2020 Jan; 25(3):. PubMed ID: 31979319
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Emicizumab, the bispecific antibody to factors IX/IXa and X/Xa, potentiates coagulation function in factor XI-deficient plasma in vitro.
    Minami H; Nogami K; Yada K; Ogiwara K; Furukawa S; Soeda T; Kitazawa T; Shima M
    J Thromb Haemost; 2019 Jan; 17(1):126-137. PubMed ID: 30444568
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro studies using a global hemostasis assay to examine the anticoagulation effects in plasma by the direct thrombin inhibitors: dabigatran and argatroban.
    He S; Wallèn H; Bark N; Blombäck M
    J Thromb Thrombolysis; 2013 Feb; 35(2):131-9. PubMed ID: 22843196
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differences in the clinically effective molar concentrations of four direct thrombin inhibitors explain their variable prothrombin time prolongation.
    Warkentin TE; Greinacher A; Craven S; Dewar L; Sheppard JA; Ofosu FA
    Thromb Haemost; 2005 Nov; 94(5):958-64. PubMed ID: 16363236
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Results of clot waveform analysis and thrombin generation test for a plasma-derived factor VIIa and X mixture (MC710) in haemophilia patients with inhibitors--phase I trial: 2nd report.
    Shirahata A; Fukutake K; Mimaya J; Takamatsu J; Shima M; Hanabusa H; Takedani H; Takashima Y; Matsushita T; Tawa A; Higasa S; Takata N; Sakai M; Kawakami K; Ohashi Y; Saito H
    Haemophilia; 2013 Mar; 19(2):330-7. PubMed ID: 22989180
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Laboratory measurements of the oral direct factor Xa inhibitor edoxaban: comparison of prothrombin time, activated partial thromboplastin time, and thrombin generation assay.
    Morishima Y; Kamisato C
    Am J Clin Pathol; 2015 Feb; 143(2):241-7. PubMed ID: 25596250
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Edoxaban, a direct factor Xa inhibitor, suppresses tissue-factor induced human platelet aggregation and clot-bound factor Xa in vitro: Comparison with an antithrombin-dependent factor Xa inhibitor, fondaparinux.
    Honda Y; Kamisato C; Morishima Y
    Thromb Res; 2016 May; 141():17-21. PubMed ID: 26962981
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Coagulation Testing in the Core Laboratory.
    Winter WE; Flax SD; Harris NS
    Lab Med; 2017 Nov; 48(4):295-313. PubMed ID: 29126301
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monitoring low molecular weight heparins at therapeutic levels: dose-responses of, and correlations and differences between aPTT, anti-factor Xa and thrombin generation assays.
    Thomas O; Lybeck E; Strandberg K; Tynngård N; Schött U
    PLoS One; 2015; 10(1):e0116835. PubMed ID: 25625201
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Contemporary Anticoagulation Reversal Focus on Direct Thrombin Inhibitors and Factor Xa Inhibitors.
    Mancl EE; Crawford AN; Voils SA
    J Pharm Pract; 2013 Feb; 26(1):43-51. PubMed ID: 23160865
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the aPTT with alternative tests for monitoring direct thrombin inhibitors in patient samples.
    Lind SE; Boyle ME; Fisher S; Ishimoto J; Trujillo TC; Kiser TH
    Am J Clin Pathol; 2014 May; 141(5):665-74. PubMed ID: 24713737
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monitoring effects of direct FXa-inhibitors with a new one-step prothrombinase-induced clotting time (PiCT) assay: comparative in vitro investigation with heparin, enoxaparin, fondaparinux and DX 9065a.
    Graff J; Picard-Willems B; Harder S
    Int J Clin Pharmacol Ther; 2007 Apr; 45(4):237-43. PubMed ID: 17474542
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Clot Waveform Analysis of Thrombin Time Using a Small Amount of Thrombin Is Useful for Evaluating the Clotting Activity of Plasma Independent of the Presence of Emicizumab.
    Wada H; Shiraki K; Matsumoto T; Suzuki K; Yamashita Y; Tawara I; Shimpo H; Shimaoka M
    J Clin Med; 2022 Oct; 11(20):. PubMed ID: 36294464
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.